Patents by Inventor Christopher Hurley
Christopher Hurley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240150364Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.Type: ApplicationFiled: November 13, 2023Publication date: May 9, 2024Applicant: Genentech, Inc.Inventors: Paul Gibbons, Emily Hanan, Wendy Liu, Joseph Lyssikatos, Steven R. Magnuson, Rohan Mendonca, Richard Pastor, Thomas E. Rawson, Michael Siu, Mark E. Zak, Aihe Zhou, Bing-Yan Zhu, Christopher Hurley
-
Publication number: 20220389020Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.Type: ApplicationFiled: January 14, 2022Publication date: December 8, 2022Applicant: Genentech, Inc.Inventors: Paul Gibbons, Emily Hanan, Wendy Liu, Joseph P. Lyssikatos, Steven R. Magnuson, Rohan Mendonca, Richard Pastor, Thomas E. Rawson, Michael Siu, Mark E. Zak, Aihe Zhou, Bing-Yan Zhu, Christopher Hurley
-
Patent number: 11008312Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein m, n, p, q A, B, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.Type: GrantFiled: April 30, 2019Date of Patent: May 18, 2021Assignee: Genentech, Inc.Inventors: Sarah M. Bronner, James J. Crawford, Andrew Cridland, Patrick Cyr, Benjamin Fauber, Emanuela Gancia, Alberto Gobbi, Christopher Hurley, Jonathan Killen, Wendy Lee, Olivier Rene, Monique Bodil Van Niel, Stuart Ward, Paul Winship, Jason Zbieg
-
Publication number: 20200002345Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.Type: ApplicationFiled: September 5, 2019Publication date: January 2, 2020Applicant: Genentech, Inc.Inventors: Paul Gibbons, Emily Hanan, Wendy Liu, Joseph P. Lyssikatos, Steven R. Magnuson, Rohan Mendonca, Richard Pastor, Thomas E. Rawson, Michael Siu, Mark E. Zak, Aihe Zhou, Bing-Yan Zhu, Christopher Hurley
-
Patent number: 10487068Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein m, n, A, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.Type: GrantFiled: November 1, 2017Date of Patent: November 26, 2019Assignee: Genentech, Inc.Inventors: Benjamin Fauber, Monique Bodil van Niel, Andrew Cridland, Christopher Hurley, Jonathan Killen, Stuart Ward
-
Publication number: 20190263794Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein m, n, p, q A, B, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.Type: ApplicationFiled: April 30, 2019Publication date: August 29, 2019Applicant: Genentech, Inc.Inventors: Sarah M. Bronner, James J. Crawford, Andrew Cridland, Patrick Cyr, Benjamin Fauber, Emanuela Gancia, Alberto Gobbi, Christopher Hurley, Jonathan Killen, Wendy Lee, Olivier Rene, Monique Bodil Van Niel, Stuart Ward, Paul Winship, Jason Zbieg
-
Patent number: 10364245Abstract: Compounds of formula (I) defined herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.Type: GrantFiled: May 23, 2018Date of Patent: July 30, 2019Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: Carmelida Capaldi, Elisabetta Armani, Christopher Hurley, Barbara Giuseppina Avitabile-Woo, Roberta Lanaro, Neil Stuart Jennings
-
Patent number: 10280144Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein m, A, X, Y, Z, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.Type: GrantFiled: November 1, 2017Date of Patent: May 7, 2019Assignee: Genentech, Inc.Inventors: Benjamin Fauber, James J. Crawford, Sarah M. Bronner, Monique Bodil van Niel, Andrew Cridland, Emanuela Gancia, Christopher Hurley, Jonathan Killen, Stuart Ward
-
Publication number: 20180354945Abstract: Compounds of formula (I) defined herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.Type: ApplicationFiled: May 23, 2018Publication date: December 13, 2018Applicant: CHIESI FARMACEUTICI S.p.A.Inventors: Carmelida CAPALDI, Elisabetta ARMANI, Christopher HURLEY, Barbara Giuseppina AVITABILE-WOO, Roberta LANARO, Neil Stuart JENNINGS
-
Patent number: 10131644Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, X1, X2, X3, X4, Y, Z, A, R1, R2, R3, R4, R5 R6, R7, R8, R9, R10, R11, R12 and R13 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis, muscular sclerosis and psoriasis.Type: GrantFiled: June 30, 2016Date of Patent: November 20, 2018Assignee: Genentech, Inc.Inventors: Monique Bodil van Niel, Benjamin Fauber, Emanuela Gancia, Simon Gaines, Alberto Gobbi, Christopher Hurley, Tammy Ladduwahetty, Olivier Rene, David Vesey, Stuart Ward, Paul Winship
-
Patent number: 10100050Abstract: Compounds of formula (I) defined herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.Type: GrantFiled: December 22, 2016Date of Patent: October 16, 2018Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: Carmelida Capaldi, Elisabetta Armani, Andrew Steven Robert Jennings, Christopher Hurley
-
Publication number: 20180222882Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein m, n, A, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.Type: ApplicationFiled: November 1, 2017Publication date: August 9, 2018Applicant: Genentech, Inc.Inventors: Benjamin Fauber, Monique Bodil van Niel, Andrew Cridland, Christopher Hurley, Jonathan Killen, Stuart Ward
-
Patent number: 9994551Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein R1, R2, R3 and R4 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.Type: GrantFiled: November 1, 2017Date of Patent: June 12, 2018Assignee: Genentech, Inc.Inventors: Benjamin Fauber, Monique Bodil van Niel, Andrew Cridland, Christopher Hurley, Jonathan Killen, Stuart Ward, Paul Winship
-
Patent number: 9994565Abstract: Compounds of formula (I) defined herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.Type: GrantFiled: December 22, 2016Date of Patent: June 12, 2018Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: Carmelida Capaldi, Elisabetta Armani, Andrew Steven Robert Jennings, Christopher Hurley
-
Patent number: 9981916Abstract: Compounds of the formula I: or a pharmaceutical salt thereof, wherein X, Ar1, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.Type: GrantFiled: November 5, 2014Date of Patent: May 29, 2018Assignee: Genentech, Inc.Inventors: Monique Bodil van Niel, Andrew Cridland, Benjamin Fauber, Alberto Gobbi, Christopher Hurley, David Hurst, Jonathan Killen, Robert Maxey, Stuart Ward
-
Publication number: 20180127410Abstract: Compounds of formula (I) defined herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.Type: ApplicationFiled: December 22, 2016Publication date: May 10, 2018Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Carmelida CAPALDI, Elisabetta ARMANI, Andrew Steven Robert JENNINGS, Christopher HURLEY
-
Publication number: 20180072683Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein m, A, X, Y, Z, R1, R2, R3, R4 and R5are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.Type: ApplicationFiled: November 1, 2017Publication date: March 15, 2018Applicant: Genentech, Inc.Inventors: Benjamin Fauber, James J. Crawford, Sarah M. Bronner, Monique Bodil van Niel, Andrew Cridland, Emanuela Gancia, Christopher Hurley, Jonathan Killen, Stuart Ward
-
Publication number: 20180051010Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein R1, R2, R3 and R4 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.Type: ApplicationFiled: November 1, 2017Publication date: February 22, 2018Applicant: Genentech, Inc.Inventors: Benjamin Fauber, Monique Bodil van Niel, Andrew Cridland, Christopher Hurley, Jonathan Killen, Stuart Ward, Paul Winship
-
Publication number: 20170283424Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.Type: ApplicationFiled: June 20, 2017Publication date: October 5, 2017Applicant: Genentech, Inc.Inventors: Paul Gibbons, Emily Hanan, Wendy Liu, Joseph P. Lyssikatos, Steven R. Magnuson, Rohan Mendonca, Richard Pastor, Thomas E. Rawson, Michael Siu, Mark E. Zak, Aihe Zhou, Bing-Yan Zhu, Christopher Hurley
-
Patent number: D991550Type: GrantFiled: May 26, 2021Date of Patent: July 4, 2023Inventor: Christopher Hurley
